Therapeutic strategies for inhibiting oncogenic BRAF signaling
E Halilovic, DB Solit - Current opinion in pharmacology, 2008 - Elsevier
Mitogen-activated protein kinase (MAPK) activation is a common property of human cancers
and is often due to activating mutations in the BRAF and RAS genes. BRAF kinase domain …
and is often due to activating mutations in the BRAF and RAS genes. BRAF kinase domain …
Targeting oncogenic BRAF in human cancer
CA Pratilas, F Xing, DB Solit - Therapeutic Kinase Inhibitors, 2011 - Springer
Abstract Mitogen Activated Protein Kinase (MAPK) pathway activation is a frequent event in
human cancer and is often the result of activating mutations in the BRAF and RAS …
human cancer and is often the result of activating mutations in the BRAF and RAS …
BRAF as a target for cancer therapy
R Dienstmann, J Tabernero - Anti-Cancer Agents in Medicinal …, 2011 - ingentaconnect.com
Tumors with mutations in the gene encoding the serine-threonine protein kinase BRAF are
dependent on the MAPK signaling pathway for their growth, what offers an opportunity to test …
dependent on the MAPK signaling pathway for their growth, what offers an opportunity to test …
Therapeutic strategies for targeting BRAF in human cancer
CA Pratilas, DB Solit - Reviews on recent clinical trials, 2007 - ingentaconnect.com
Constitutive ERK activation is a common finding in human cancer and is often the result of
activating mutations of BRAF and RAS. BRAF missense mutations occur in approximately …
activating mutations of BRAF and RAS. BRAF missense mutations occur in approximately …
Molecular targeting of the BRAF proto-oncogene/mitogen-activated protein kinase (MAPK) pathway across cancers
KS Shan, TU Rehman, S Ivanov, G Domingo… - International Journal of …, 2024 - mdpi.com
The mitogen-activated protein kinase (MAPK) pathway is essential for cellular proliferation,
growth, and survival. Constitutive activation of this pathway by BRAF mutations can cause …
growth, and survival. Constitutive activation of this pathway by BRAF mutations can cause …
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …
[HTML][HTML] BRAF inhibitors in clinical oncology
Activating mutations of the BRAF oncogene are present in approximately 5-10% of all
human malignancies and lead to constitutive activation of the mitogen activated protein …
human malignancies and lead to constitutive activation of the mitogen activated protein …
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
M Holderfield, MM Deuker, F McCormick… - Nature Reviews …, 2014 - nature.com
The identification of mutationally activated BRAF in many cancers altered our conception of
the part played by the RAF family of protein kinases in oncogenesis. In this Review, we …
the part played by the RAF family of protein kinases in oncogenesis. In this Review, we …
[HTML][HTML] Biological challenges of BRAF inhibitor therapy
I Puzanov, P Burnett, KT Flaherty - Molecular Oncology, 2011 - Elsevier
Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
as being most prevalent in melanoma in 2002. Only recently have potent and selective …
Molecular pathways and mechanisms of BRAF in cancer therapy
With the identification of activating mutations in BRAF across a wide variety of malignancies,
substantial effort was placed in designing safe and effective therapeutic strategies to target …
substantial effort was placed in designing safe and effective therapeutic strategies to target …